# ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin

> **NCT02435927** · PHASE1 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ASLAN001+ CAPOX (Oxaliplatin, capecitabine)
- **DRUG:** ASLAN001 + mFolfox6 (5-FU, leucovorin)

## Key facts

- **NCT ID:** NCT02435927
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2021-06
- **Final completion:** 2021-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-04-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435927, "ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02435927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*